Edition:
United States

Argos Therapeutics Inc (ARGS.OQ)

ARGS.OQ on NASDAQ Stock Exchange Global Market

0.16USD
15 Dec 2017
Change (% chg)

$0.01 (+5.27%)
Prev Close
$0.15
Open
$0.15
Day's High
$0.16
Day's Low
$0.15
Volume
621,484
Avg. Vol
898,470
52-wk High
$5.65
52-wk Low
$0.13

Chart for

About

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company's Arcelis technology platform utilizes biological... (more)

Overall

Beta: 1.35
Market Cap(Mil.): $13.69
Shares Outstanding(Mil.): 87.88
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.20 16.04
EPS (TTM): -- -- --
ROI: -- 15.06 34.69
ROE: -- 16.55 15.46

BRIEF-Argos Therapeutics Enters Into Agreement With Saint-Gobain Performance Plastics Corp

* ARGOS THERAPEUTICS - ‍ON NOV 22, ENTERED INTO A SATISFACTION AND RELEASE AGREEMENT WITH SAINT-GOBAIN PERFORMANCE PLASTICS CORP - SEC FILING

Nov 28 2017

BRIEF-Argos Provides Financial Update

* ARGOS THERAPEUTICS - ‍TKC PROPERTIES HAS, WITH ARGOS' FULL CONSENT, SUCCESSFULLY COMPLETED SALE OF FACILITY IN DURHAM COUNTY, NC TO A THIRD PARTY​

Nov 28 2017

BRIEF-Argos reports third quarter financial results

* Argos reports third quarter 2017 financial results and operational highlights

Nov 09 2017

BRIEF-Argos Therapeutics files for offering of 13.5 mln shares of common stock by Invetech

* Argos Therapeutics files for offering of 13.5 million shares of common stock by Invetech Pty Ltd - SEC filing Source text: (http://bit.ly/2zcHDkV) Further company coverage:

Nov 03 2017

BRIEF-Argos Therapeutics enters into agreement with Invetech

* Argos Therapeutics - On September 22, 2017 co entered into a satisfaction and release agreement with Invetech PTY Ltd ‍​ - SEC filing

Sep 25 2017

BRIEF-‍Argos doses first HIV patient with AGS-004

* ‍Argos announces first dosing of HIV patient with AGS-004 derived from latent viral reservoir​

Sep 06 2017

BRIEF-Argos Therapeutics files for possible resale up to 18.9 mln shares

* Argos Therapeutics Inc files for possible resale up to 18.9 million shares of common stock of argos therapeutics, inc. By pharmstandard international s.a Source text: (http://bit.ly/2uQ9e6l) Further company coverage:

Aug 16 2017

BRIEF-Argos Therapeutics Q2 loss per share $ 0.21

* Argos Therapeutics reports second quarter 2017 financial results and recent operational highlights

Aug 09 2017

Earnings vs. Estimates